Xl888 Melanoma

A STATement On Vemurafenib-resistant melanoma.
A STATement on Vemurafenib-Resistant Melanoma Edward J. Hartsough and Andrew E. Aplin Department of Cancer Biology and Kimmel Cancer Center, Thomas Jefferson University, ... Fetch Content

In Vivo Model Of NRAS Mutant melanoma
Treatment of a panel of nine NRAS mutant human melanoma cell lines with XL888 (Figure 1) was associated with concentration-dependent decreases in cell growth (Figure ... Read Content

2014 ANNUAL REPORT
Cancer Center went on to conduct additional preclinical work showing activity of XL888 in vemurafenib-resistant melanoma models, the results of which provided the rationale for the initiation of an investigator- ... Fetch Content

Q3 2014 Financial Results
2 Forward-Looking Statements This presentation, including any oral presentation accompanying it, contains forward-looking statements, including, without limitation, ... Retrieve Doc

Clinical Implications Of CD8& T-Cell Infiltration In Frequent ...
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 18:2502–14 Straussman R, Morikawa T, melanoma, which blocks the inhibitory receptor CTLA-4 on T cells, resulting in enhanced T-cell activation. Additional ... Get Content Here

The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance ...
Figure 1. The HSP90 inhibitor XL888 blocks the growth and survival of melanoma cell lines with diverse mechanisms of vemurafenib resistance. A, growth ... Read Here

Inhibition Of Wee1, AKT, And CDK4 Underlies The Ef In Vivo ...
Chemical Therapeutics Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma ... Read More

Researchers Find Potential Solution To melanoma's Resistance ...
Melanoma's resistance to vemurafenib 28 February 2012 Researchers at Moffitt Cancer Center in Tampa, HSP90 with XL888 and vemurafenib in treating melanoma patients in order to limit or prevent chemotherapy resistance." Provided by H. Lee Moffitt Cancer Center & ... Access Doc

A STATement On Vemurafenib-Resistant Melanoma
A STATement on Vemurafenib-Resistant Melanoma Edward J. Hartsough1 and Andrew E. Aplin1 Despite recent advancements in the treatment of late-stage mutant BRAF V600E/K ... Fetch Here

Significance Of Long Term Pharmacodynamic Actions Of The ...
XL888, a novel, synthetic, orally bioavailable inhibitor of HSP90. AACR-NCI-EORTC 2008. Abstract 144. 4. melanoma cell lines that harbour B-Raf or N-Ras mutations. AACR Annual meeting April 2008. Abstract 4764. 8. ... Read More

Appendix
The hsp90 inhibitor xl888 overcomes braf inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 18, 2502-2514 (2012). Pten loss confers braf inhibitor resistance to melanoma cells through the suppression of bim expression. Cancer Research. 71, 2750-2760 (2011). ... Visit Document

Supplementary Materials For
Supplementary Materials for Fig. S7. The HSP90 inhibitor XL888 overcomes intrinsic and acquired vemurafenib resistance. Table S1. melanoma cells 72 h after treatment with DMSO or combination of vemurafenib (6 µM) with a ... Access This Document

Exelixis - Wikipedia, The Free Encyclopedia
XL888, a synthetic inhibitor of HSP90, a chaperone protein that promotes the activity and stability of a range of regulatory proteins, including kinases. [1] melanoma, breast, non-small cell lung, hepatocellular, kidney. ... Read Article

XLVISION XLFOCUS XLEXCELLENCE
XL888 is a novel, synthetic, orally bioavailable inhibitor of HSP90, a chaperone protein that promotes the activity and stability of a range of key regulatory proteins including kinases. NSCLC, melanoma and papillary thyroid cancer. ... Retrieve Full Source

Paraiso Research Summary 4-4-12
Nearly 50% of melanoma tumors harbor a mutant BRAF protein. We found that treatment of this cell line panel with XL888, an HSP90 inhibitor, led to the degradation or inhibition of all proteins implicated so far in vemurafenib resistance. ... Retrieve Document

Kim H. T. Paraiso NIH Public Access 1 1,# Elizabeth Wood1 ...
Melanoma cell lines treated with XL888 (300 nM) for 48 hrs. (Right) Quantitative RT-PCR showing that XL888 (300 nM, 48hrs) treatment downregulates Mcl-1 expression at the Paraiso et al. Page 22 Clin Cancer Res. Author manuscript; available in PMC 2013 May 01. ... View This Document

Evaluating Dual Hsp90 And Hsp70 Inhibition As A Cancer Therapy
XL888 Melanoma I 2012 Dual Vemurafenib Evaluating Dual Hsp90 and Hsp70 Inhibition as a Cancer Therapy. Similartothestresscausedbyhightemperatures,theexcessivegrowthofcancer createsstressincells,andthuscancercellsproducehighlevelsofHsps.TheseHsps ... Retrieve Content